FHIR IG analytics

Resources that use this resource

No resources found

Resources that this resource uses

No resources found

Narrative

Note: links and images are rebased to the (stated) source

Source1

{
  "resourceType": "Group",
  "id": "179619",
  "meta": {
    "versionId": "5",
    "lastUpdated": "2025-03-15T21:15:32.464Z",
    "profile": [
      "http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-eligibility-criteria"
    ]
  },
  "language": "en",
  "text": {
    "status": "empty",
    "div": "<!-- snip (see above) -->"
  },
  "extension": [
    {
      "url": "http://hl7.org/fhir/StructureDefinition/artifact-author",
      "valueContactDetail": {
        "name": "Brian S. Alper"
      }
    },
    {
      "url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as",
      "valueMarkdown": "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179619. Revised 2023-12-06. Available at: https://fevir.net/resources/Group/179619. Computable resource at: https://fevir.net/resources/Group/179619#json."
    },
    {
      "url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
            "code": "active",
            "display": "Active"
          }
        ]
      }
    }
  ],
  "url": "https://fevir.net/resources/Group/179619",
  "identifier": [
    {
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code": "ACSN",
            "display": "Accession ID"
          }
        ],
        "text": "FEvIR Object Identifier"
      },
      "system": "https://fevir.net/FOI",
      "value": "179619",
      "assigner": {
        "display": "Computable Publishing LLC"
      }
    }
  ],
  "name": "SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer",
  "title": "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer",
  "status": "active",
  "publisher": "Computable Publishing LLC",
  "contact": [
    {
      "telecom": [
        {
          "system": "email",
          "value": "support@computablepublishing.com"
        }
      ]
    }
  ],
  "description": "**Study selection criteria**\nTypes of Studies.\nRandomized controlled clinical trials (RCTs) with parallel design that compared the association of ADT and chemotherapy (docetaxel), versus ADT alone.\n\nTypes of participants.\nPatients aged ≥18 years with cytological or histological diagnosis of mHNPC.",
  "useContext": [
    {
      "code": {
        "system": "https://fevir.net/resources/CodeSystem/179423",
        "code": "evidence-communication",
        "display": "Evidence Communication"
      },
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "SystematicReviewEligibilityCriteria",
            "display": "SystematicReviewEligibilityCriteria"
          }
        ]
      }
    }
  ],
  "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "membership": "conceptual",
  "combinationMethod": "all-of",
  "characteristic": [
    {
      "code": {
        "text": "Study Design"
      },
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "https://fevir.net/sevco",
            "code": "SEVCO:01003",
            "display": "randomized assignment"
          }
        ]
      },
      "exclude": false,
      "description": "Randomized controlled clinical trials (RCTs)"
    },
    {
      "code": {
        "text": "Study Design"
      },
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "https://fevir.net/sevco",
            "code": "SEVCO:01011",
            "display": "Parallel cohort design"
          }
        ]
      },
      "exclude": false,
      "description": "parallel design"
    },
    {
      "code": {
        "text": "Comparison"
      },
      "valueReference": {
        "type": "EvidenceVariable",
        "display": "GroupAssignment: ADT plus docetaxel vs. ADT alone"
      },
      "exclude": false,
      "description": "compared the association of ADT and chemotherapy (docetaxel), versus ADT alone"
    },
    {
      "code": {
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "397669002",
            "display": "Age"
          }
        ]
      },
      "valueQuantity": {
        "value": 18,
        "comparator": ">=",
        "unit": "years",
        "system": "http://unitsofmeasure.org",
        "code": "a"
      },
      "exclude": false,
      "description": "Types of participants.\nPatients aged ≥18 years",
      "method": [
        {
          "text": "applied to participants in the studies"
        }
      ]
    },
    {
      "code": {
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "64572001",
            "display": "Disease (disorder)"
          }
        ]
      },
      "valueCodeableConcept": {
        "text": "metastatic hormone-naive prostate cancer"
      },
      "exclude": false,
      "description": "Types of participants.\nPatients with cytological or histological diagnosis of mHNPC.",
      "method": [
        {
          "text": "applied to participants in the studies"
        },
        {
          "text": "cytological or histological diagnosis"
        }
      ]
    }
  ]
}